Chair

Dr. Dagmar CHASE  
BVMA e.V.  
Phone: +49 89 930 54 48  
Mobile: +49 172 85 36 338  
E-mail: [dagmar.chase@clinrex.com](mailto:dagmar.chase@clinrex.com)

The EUCROF Clinical Trials Legislation Working Group (CTL WG) is aimed to represent European CROs when input is sought from stakeholders by legislators (e.g., EMA, EU Commission) or international organisations (e.g., ICH, WHO) in the context of new provisions for clinical trials. It is crucial that CROs provide their perspectives and opinions as CROs are involved in 60 – 70 % of all clinical trials worldwide. The delegation of sponsor duties and functions to CROs is important to be taken into account when legal regulations and guidance documents are developed. EUCROF does not miss this chance and continuously participates in the consultation rounds offered by legislators and/or international organisations.

The CTL WG is in operation since more than 15 years and has given input to numerous documents with latest activities on the “ICH Guideline E6(R3) (ICH-GCP)”.

It is our mission to effectively use the voice we have through the European CRO Federation.

We are looking forward to continuing our active involvement in the development of Clinical Trials documents.

Members

WG Chair: Dr. Dagmar Chase

WG Members – David Ruwe (SGS proDERM - Germany), Ulrike Lorch (Richmond Pharmacology - UK), Alexandra Koulouri (Qualitis - Greece), Catherine Ferre (ICON - France), Mihaela David (PSI CRO - Romania), Tineke de Boer (ICON - The Netherlands), Cari Joacobs-Blom (CR2O - The Netherlands), Yuriy Lebed (Pharmaxi - Ukraine), Cristina Manfredi (CVBF - Italy), Phaedra Mavroidi (Qualitis - Greece). [GUEST MEMBERS: Giorgio Reggiadro (CVBF – Italy), Dilshat Djumanov (Richmond Pharmacology - UK)].